Corrigendum: Exploring the impact of HDL and LMNA gene expression on immunotherapy outcomes in NSCLC: a comprehensive analysis using clinical & gene data

Corrigendum: Exploring the impact of HDL and LMNA gene expression on immunotherapy outcomes in NSCLC: a comprehensive analysis using clinical & gene data

Saved in:

Bibliographic Details
Main Authors:	Jingru Li, Jingting Wang, Bangwei Cao
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-02-01
Series:	Frontiers in Oncology
Subjects:	non-small cell lung cancer immune checkpoint inhibitor therapy high-density lipoprotein enrich analysis machine learning LMNA
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1575160/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Case Report: Concurrent de novo pathogenic variants in the LMNA gene as a cause of sporadic partial lipodystrophy
by: José L. Santos, et al.
Published: (2024-11-01)

LMNA-Cardiomyopathy in Emery-Dreifuss Muscular Dystrophy
by: E. V. Resnik, et al.
Published: (2024-10-01)

Cardiac Phenotype Associated with Two Heterozygous <i>LMNA</i> Variants
by: Aura Siikjärvi, et al.
Published: (2025-05-01)

LAMIN A/C GENE (LMNA) MUTATIONS IN PATIENTS WITH DILATED CARDIOMYOPATHY AND THEIR PHENOTYPIC MANIFESTATION
by: T. G. Vaikhanskaya, et al.
Published: (2016-03-01)

CRYOVATE: A Pilot Study of Lung Cancer Cryoactivation in Combination With Immunotherapy in Advanced NSCLC
by: Antoine Desilets, MD, MSc, et al.
Published: (2024-12-01)

A novel model for predicting immunotherapy response and prognosis in NSCLC patients
by: Ting Zang, et al.
Published: (2025-05-01)

Genetic spectrum of familial and sporadic dilated cardiomyopathy: arrhythmic phenotypes associated with mutations in the lamin A/C (LMNA) gene
by: T. G. Vaikhanskaya, et al.
Published: (2023-05-01)

Optimal immunotherapy duration in advanced NSCLC: defining the ideal treatment window
by: Kaibo Ding, et al.
Published: (2025-03-01)

Liraglutide use in pediatric type 2 familial partial lipodystrophy caused by LMNA mutation: a case report
by: Youran Li, et al.
Published: (2025-07-01)

Adjuvant immunotherapy improves survival in completely resected stage IB–III NSCLC: a systematic review and meta-analysis
by: Hong Huang, et al.
Published: (2025-04-01)

Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance
by: Jin Tian, et al.
Published: (2024-12-01)

Lipidomics reveals biomarkers of the efficacy of first-line ICI therapy combined with chemotherapy in NSCLC
by: Jia Yu, et al.
Published: (2025-06-01)

The relationship between non-HDL-C/HDL-C ratio and bone mineral density: an NHANES study
by: Shuo Qi, et al.
Published: (2025-01-01)

Characteristics and innovative points of clinical trials of radiotherapy combined with immune checkpoint inhibitors in NSCLC over the past decade
by: Mengting Li, et al.
Published: (2025-07-01)

The role of novel risk-scoring systems in predicting the efficacy of immunotherapy
by: Yu.V. Moskalenko
Published: (2025-02-01)

Clinical efficacy analysis of cross-line immunotherapy in driver gene-negative advanced non-small cell lung cancer patients
by: WANG Yuankun, et al.
Published: (2025-02-01)

Imaging features and prognostic significance of immune checkpoint inhibitor–related pneumonitis in NSCLC
by: Xueqi Wang, et al.
Published: (2025-07-01)

The association of the non-HDL-cholesterol to HDL-cholesterol ratio (NHHR) with obstructive sleep apnea among adults aged ≥ 40 years: results from NHANES 2015–2018
by: Lvao Chen, et al.
Published: (2025-05-01)

Association Between Non-HDL to HDL Cholesterol Ratio (NHHR) and Psoriasis in Adults: A Cross-Sectional Study Using 2009–2014 Data
by: Jiang Y, et al.
Published: (2024-11-01)

Immunotherapy concurrently administered with chemoradiotherapy in limited-stage small-cell lung cancer
by: Liuhua Long, et al.
Published: (2025-07-01)

Comparative Efficacy of PD‐1 Inhibitor‐Based Neoadjuvant Chemoimmunotherapy Regimens for Resectable Stage II–IIIa NSCLC: A Real‐World Retrospective Study
by: Bo Yan, et al.
Published: (2025-07-01)

Liquid biopsy using plasma proteomics in predicting efficacy and tolerance of PD-1/PD-L1 blockades in NSCLC: a prospective exploratory study
by: Yuan Gao, et al.
Published: (2025-07-01)

The role of COPD in survival of NSCLC patients receiving immune checkpoint inhibitors: A meta-analysis
by: Yan Zhu, et al.
Published: (2025-05-01)

Immunotherapy in Non-Small-Cell Lung Cancer: A Modified Delphi Survey Consensus on First Line Treatment, Special Populations and Rechallenge
by: Francesca Colonese, et al.
Published: (2024-11-01)

Curative immunotherapy-based strategies for non-metastatic non-small cell lung cancer
by: Justin J. Kuhlman, et al.
Published: (2024-12-01)

Multi-omics analysis reveals the sensitivity of immunotherapy for unresectable non-small cell lung cancer
by: Rui Wu, et al.
Published: (2025-02-01)

Effects of Bojungikki-Tang on immune response and clinical outcomes in NSCLC patients receiving immune checkpoint inhibitors: a randomized pilot study
by: Mi Mi Ko, et al.
Published: (2025-07-01)

Impact of thyroid immune-related adverse events on clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibitor therapy: A single center study
by: Šejla Cerić, et al.
Published: (2025-03-01)

Dropped head related lamin A/C associated congenital muscular dystrophy case; previously defined as emerydreifuss muscular dystrophy
by: Hande Tekin, et al.
Published: (2020-02-01)

The association between HDL-c levels and computed tomography-based osteosarcopenia in older adults
by: Rongzhou Wang, et al.
Published: (2024-11-01)

Ginseng polysaccharides circumvent acquired resistance to anti-PD-1 immunotherapy in patients with non-small cell lung cancer
by: Jumin Huang, et al.
Published: (2025-02-01)

Baseline 18F-FDG PET/CT parameters in predicting the efficacy of immunotherapy in non-small cell lung cancer
by: Lu Zheng, et al.
Published: (2025-01-01)

Efficacy and safety of immunotherapy combined with chemotherapy in patients with ES‐SCLC: A systematic review and network meta‐analysis of RCTs and RWSs
by: Runting Kang, et al.
Published: (2024-11-01)

Gut microbes and immunotherapy for non-small cell lung cancer: a systematic review
by: Yali Jin, et al.
Published: (2025-05-01)

The Role of Non-HDL Cholesterol and Apolipoprotein B in Cardiovascular Disease: A Comprehensive Review
by: Vasiliki Katsi, et al.
Published: (2025-07-01)

Immunotherapy for Extensive-stage Small Cell Lung Cancer:  Research Progress and Future Perspectives
by: Yuling ZHONG, et al.
Published: (2024-11-01)

HDL‐Apolipoprotein in Alzheimer's Disease Revisited: From Periphery to CNS
by: Yihong Huang, et al.
Published: (2025-04-01)

Impact of metabolic and nutritional disorders on the synergy between radiotherapy and immunotherapy in non-small-cell lung cancer
by: Haiyan Chen, et al.
Published: (2025-05-01)

Understanding the heterogeneity and dysfunction of HDL in chronic kidney disease: insights from recent reviews
by: Zhen Xu, et al.
Published: (2024-11-01)

Inflammatory markers predict efficacy of immunotherapy in advanced non-small cell lung cancer: a preliminary exploratory study
by: Yingqing Zhang, et al.
Published: (2025-01-01)